CJC-1295
Also known as: CJC1295, GRF(1-29) analog, hGRF(1-29) albumin bioconjugate, long-acting GHRH analog, DAC:GRF
Growth Hormone-Releasing Hormone (GHRH) Analogue / Growth Hormone Secretagogue
What it is
CJC-1295 is a peptide people use to raise their growth hormone levels for muscle building, fat loss, and recovery. It works by extending the action of a natural hormone that tells the pituitary to release growth hormone. Not FDA-approved; banned by WADA; classified as a prohibited performance-enhancing substance.
The scientific side
CJC-1295 is a synthetic analogue of human growth hormone-releasing hormone (GHRH/hGRF 1-29). It incorporates a reactive maleimidopropionic acid group (Drug Affinity Complex, DAC) at its C-terminus that allows covalent binding to free thiols on endogenous plasma proteins, primarily serum albumin (Cys34), markedly extending its plasma half-life to approximately 5.8–8.1 days in humans. By acting as a long-lasting GHRH receptor agonist at anterior pituitary somatotrophs, CJC-1295 stimulates dose-dependent increases in GH secretion and downstream IGF-1 production. GH pulsatility is preserved, but trough (basal) GH levels are markedly elevated, which appears to drive the observed increases in IGF-1. In rodent models, CJC-1295 has been shown to activate IGF-1 signalling and satellite cell repair pathways, rescue growth deficits in GHRH-knockout mice by promoting somatotroph proliferation, and restore normal pituitary size, GH, and IGF-1 levels in brain-specific M3 muscarinic receptor knockout mice. It demonstrates enhanced in vitro stability against dipeptidylpeptidase-IV compared to native GHRH. This entry covers the DAC form only. CJC-1295 without DAC (Mod GRF 1-29) has its own entry: the same tetrasubstituted GRF(1-29) peptide without the DAC group, so it does not bind albumin, has a half-life of roughly 30 minutes, and is dosed 1-3 times daily rather than weekly.
Class: Growth Hormone-Releasing Hormone (GHRH) Analogue / Growth Hormone Secretagogue
At a glance
| What it is | A modified GRF(1-29) with a chemical "drug affinity complex" (DAC) that latches onto albumin in the blood, so one injection lasts about a week. |
|---|---|
| FDA status | Not approved for any use. In December 2024 an FDA advisory committee voted 0-13 against letting compounding pharmacies make it. |
| Used for | Raising growth hormone and IGF-1 with a once-weekly injection. |
| Human evidence | Two small 2006 studies in healthy adults; a phase 2 trial in HIV was terminated in 2006. |
| Half-life | About 6-8 days (5.8-8.1 days in healthy adults). |
| Banned in sport | Yes. WADA names CJC-1295 under S2.2.4, prohibited at all times. |
What is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone. Its core is a "tetrasubstituted" GRF(1-29), the same 29-amino-acid sequence as Sermorelin with four amino acids swapped, plus a reactive group attached at the end. That group, the drug affinity complex (DAC), bonds to albumin in the blood after injection.
The name causes confusion. In research papers "CJC-1295" means the DAC version. Vendors also sell "CJC-1295 without DAC", which is the same backbone without the albumin anchor and is better known as Mod GRF 1-29. They behave very differently.
How does it work?
Like natural GHRH, CJC-1295 binds GHRH receptors on the pituitary and triggers growth hormone release, which raises IGF-1. Bonding to albumin protects it from breakdown and keeps it circulating for days instead of minutes.
A study in healthy young men found that growth hormone kept its natural pulses a week after a single dose: trough and average levels rose, but pulsatility was preserved.
Pharmacokinetics
| Half-life | 5.8-8.1 days (healthy adults, subcutaneous) |
|---|---|
| Metabolism | Bonds to albumin (cysteine 34) after injection, which protects it from enzyme breakdown |
| Clearance | Not characterized in humans |
| Route | Subcutaneous injection; studied as single, weekly and every-other-week doses |
Is it FDA-approved?
No. CJC-1295 has never been approved for any use.
FDA lists it among bulk substances that may present significant safety risks in compounding, noting immunogenicity and impurity concerns and that "FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction." As of April 2026 it appears under "nominated but withdrawn".
In December 2024, FDA's Pharmacy Compounding Advisory Committee voted against adding any CJC-1295 form to the 503A bulks list: 0-13 for each DAC form and for the free base, and 1-12 for the acetate.
- WADA: S2.2.4 Growth hormone releasing factors (named among GHRH analogues; prohibited at all times)
History
CJC-1295 came out of ConjuChem, a Montreal biotech that attached peptides to albumin to make them last longer. A 2005 rat study picked CJC-1295 from several candidates because it stayed in plasma beyond 72 hours.
In 2006 two studies in healthy adults showed growth hormone and IGF-1 stayed raised for days after one injection. A phase 2 trial in people with HIV and excess visceral fat started in December 2005 and was terminated in 2006. ConjuChem filed for bankruptcy in 2010. By then CJC-1295 was already turning up in unlabeled products seized by anti-doping labs.
Regulatory timeline
- By September 2024FDA lists CJC-1295 among other bulk drug substances that may present significant safety risks, citing increased heart rate and a systemic vasodilatory reaction. Source
- December 4, 2024FDA's Pharmacy Compounding Advisory Committee votes against all CJC-1295 forms for the 503A bulks list: 0-13 for the DAC forms and free base, 1-12 for the acetate. Source
- April 2026FDA's page lists CJC-1295 under "nominated but withdrawn". Source
- As of October 2026Still not FDA-approved. It was not on the July 2026 advisory committee agenda. Source
Side effects
In the 2006 dose-finding studies, CJC-1295 was "safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg". FDA separately notes serious adverse events including increased heart rate and a systemic vasodilatory reaction (flushing and blood vessel widening).
Because each dose keeps growth hormone and IGF-1 raised for more than a week, effects can't be stopped quickly after an injection. Long-term safety has not been studied.
Who should not use it
- No established contraindications: CJC-1295 never completed development.
- Competitive athletes: Prohibited at all times under WADA S2.2.4 (growth hormone releasing factors), per the 2026 World Anti-Doping Code Prohibited List. Verified against the current WADA list as of October 2026.
- Active cancer: it raises growth hormone and IGF-1, growth factors that approved GH-releasing drugs list as a contraindication.
- Heart rhythm or blood pressure problems: FDA notes increased heart rate and vasodilatory reactions.
Two 2006 dose-finding trials in healthy adults; FDA safety notes on its compounding risk page.
What does the research show?
In two randomized, placebo-controlled trials in healthy adults aged 21-61, a single injection raised average growth hormone 2- to 10-fold for 6 days or more, and IGF-1 1.5- to 3-fold for 9-11 days. After repeated weekly or every-other-week doses, IGF-1 stayed above baseline for up to 28 days. The estimated half-life was 5.8-8.1 days.
These were short studies of hormone levels in healthy people. No published trial has measured muscle, fat, sleep or other outcomes people use it for, and the doses commonly used online are below the doses studied.
Studied for
- Growth hormone and IGF-1 levels in healthy adults (2006 trials)
- Visceral fat in HIV (phase 2, terminated 2006)
- Growth hormone release and plasma persistence in rats (animal study)
FAQ
Is CJC-1295 the same as Mod GRF 1-29?
No. Both share the same modified GRF(1-29) backbone, but CJC-1295 adds a DAC group that binds albumin and lasts about a week. Mod GRF 1-29 (sold as "CJC-1295 without DAC") lasts minutes.
Sources: [1]
How long does CJC-1295 last?
Its half-life was 5.8-8.1 days in healthy adults, and one injection kept IGF-1 raised for 9-11 days.
Sources: [2]
Is CJC-1295 FDA-approved?
No. Its developer stopped before approval, and in 2024 an FDA advisory committee voted 0-13 against compounding the DAC forms.
Sources: [5]
Does CJC-1295 stop natural growth hormone pulses?
Not in the one study that checked: a week after a dose, growth hormone was higher but still pulsatile.
Sources: [3]
What side effects has FDA noted?
FDA cites serious adverse events including increased heart rate and a systemic vasodilatory reaction, and says clinical data are limited.
Sources: [4]
Is CJC-1295 banned in sport?
Yes. The 2026 WADA Prohibited List names CJC-1295 under S2.2.4, prohibited at all times.
Sources: [10]
Was CJC-1295 tested for muscle or fat loss?
Not in any published trial. A phase 2 trial of visceral fat in HIV was terminated in 2006 without published results.
Sources: [6]
Citations
- Jetté L, et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. PMID 15817669
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. PMID 16352683
- Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab 2006. PMID 17018654
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA: final summary minutes of the Pharmacy Compounding Advisory Committee meeting, December 4, 2024. fda.gov/media/185642/download
- NCT00267527: Phase 2 study of CJC 1295 for 12 weeks in HIV-infected patients with HIV-associated visceral obesity (ConjuChem; terminated). clinicaltrials.gov/study/NCT00267527
- ConjuChem announces Bankruptcy Act filing. Newswire, 2010. newswire.ca/news-releases/conjuchem-announces-bankruptcy-act-filing-544815902.html
- Henninge J, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal 2010. PMID 21204297
- Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295 results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res 2009. PMID 19386527
- World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Sources
- Jetté 2005. Jetté L, et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. pubmed.ncbi.nlm.nih.gov/15817669
- Teichman 2006. Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. pubmed.ncbi.nlm.nih.gov/16352683
- Ionescu 2006. Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab 2006. pubmed.ncbi.nlm.nih.gov/17018654
- Sackmann-Sala 2009. Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295 results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res 2009. pubmed.ncbi.nlm.nih.gov/19386527
- Henninge 2010. Henninge J, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal 2010. pubmed.ncbi.nlm.nih.gov/21204297
- ClinicalTrials.gov. NCT00267527: Phase 2 study of CJC 1295 for 12 weeks in HIV-infected patients with HIV-associated visceral obesity (ConjuChem; terminated). clinicaltrials.gov/study/NCT00267527
- ConjuChem, 2010. ConjuChem announces Bankruptcy Act filing. Newswire, 2010. newswire.ca/news-releases/conjuchem-announces-bankruptcy-act-filing-544815902.html
- FDA. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA (2024 archive). FDA: the same page as archived September 28, 2024. web.archive.org/web/20240928064141/https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA PCAC, December 2024. FDA: final summary minutes of the Pharmacy Compounding Advisory Committee meeting, December 4, 2024. fda.gov/media/185642/download
- WADA. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Administration & storage
- Administration
- Subcutaneous injection in human clinical trials (PMID: 16352683)Subcutaneous injection in rat studies (PMID: 15817669)Intravenous administration in rat pharmacokinetic/metabolism studies (PMID: 26879649)Injection route not further specified in some human studies (PMID: 1701865419386527)
- Storage
- The reviewed abstracts do not describe storage conditions for CJC-1295. One anti-doping study noted that urine samples containing GHRH analogues (including CJC-1295) should be handled properly to avoid degradation, with sermorelin and its metabolite found to rapidly degrade at temperatures >4 °C and pH values <7; stability of CJC-1295 itself under those conditions was not separately quantified.
- Cautions
- CJC-1295 is not approved by any regulatory authority for performance enhancement or general clinical use; human safety data beyond short-term pharmacokinetic studies are lacking.,Potential adverse effects associated with GH-axis modulation (including prolactin/cortisol elevations, appetite changes, dysglycaemia, fluid retention, myalgia/arthralgia, and injection-site reactions) have been reported in the context of GH-axis peptides in this class; specific long-term safety data for CJC-1295 are not available from the reviewed literature.,Products sold outside regulated channels may be mislabelled or contaminated; an illicitly manufactured pharmaceutical preparation containing CJC-1295 was identified by Norwegian police and customs authorities in 2009.,CJC-1295 is classified as a prohibited substance by WADA; use by competitive athletes carries significant anti-doping consequences.,Sterile technique is essential for any injectable compound to minimise infection risk.
Legal & regulatory status
Not approved by the FDA for any indication. Classified as a prohibited performance-enhancing substance by WADA. (PMID: 41966639, 41880199, 31849 — see WADA status below)
Prohibited by the World Anti-Doping Agency (WADA) under Section S2 of the Prohibited List as a growth hormone-releasing hormone analogue.
Not stated in reviewed literature — requires manual verification
What it's studied for
- Stimulation of GH and IGF-1 secretion in healthy adults (pharmacokinetic/pharmacodynamic characterisation) Human RCT
- Two randomised, placebo-controlled, double-blind, ascending-dose trials (durations 28 and 49 days) in healthy adults (ages 21–61 yr). Single sc injection produced dose-dependent 2- to 10-fold increases in mean plasma GH for ≥6 days and 1.5- to 3-fold increases in IGF-I for 9–11 days. Estimated half-life 5.8–8.1 days. M PMID 16352683 Teichman SL et al. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Clinical trial in healthy men aged 20–40 yr. A single injection of CJC-1295 (60 or 90 µg/kg) increased trough GH levels 7.5-fold (P<0.0001), mean GH 46% (P<0.01), and IGF-I 45% (P<0.001) while preserving GH pulsatility. No significant difference between the two doses. PMID 17018654 Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-4797.
- Identification of GH/IGF-1-related serum protein biomarkers Human observational
- Sera from 11 healthy young adult men analysed by 2D gel electrophoresis before and 1 week after CJC-1295 injection. Apolipoprotein A1 and transthyretin isoforms decreased; beta-hemoglobin and C-terminal albumin fragments increased. A linear relationship was found between an immunoglobulin/albumin fragment spot and IGF- PMID 19386527 Sackmann-Sala L et al. Growth Horm IGF Res. 2009;19(3):242-248.
- Normalisation of growth in GHRH-deficient (knockout) mice Animal studies only
- Three groups of 1-week-old GHRHKO mice treated for 5 weeks with 2 µg CJC-1295 every 24, 48, or 72 hours. Daily dosing normalised body weight, length, and bone length. Less frequent dosing produced partial improvements. CJC-1295 increased total pituitary RNA and GH mRNA, consistent with somatotroph proliferation. PMID 16822960 Alba M et al. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-1294.
- In Sprague-Dawley rats, CJC-1295 (the best-performing of three maleimido derivatives of hGRF(1-29)) produced a 4-fold increase in GH AUC over 2 h compared with hGRF(1-29). CJC-1295 was detectable in plasma beyond 72 h and formed a covalent albumin conjugate within 15 min persisting beyond 24 h. PMID 15817669 Jetté L et al. Endocrinology. 2005;146(7):3052-3058.
- Rescue of growth deficit in brain-specific M3 muscarinic receptor knockout mice Animal studies only
- Treatment of Br-M3-KO mice (dwarf phenotype, anterior pituitary hypoplasia) with CJC-1295 rescued the growth deficit, restoring normal pituitary size and normal serum GH and IGF-1 levels, supporting a model in which central M3 receptors regulate hypothalamic GHRH neuronal function. PMID 19332789 Gautam D et al. Proc Natl Acad Sci USA. 2009;106(16):6829-6834.
- Improvement of muscle performance in glucocorticoid-induced muscle loss (murine model) Animal studies only
- CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss. Findings are limited to animal studies. PMID 41476424 Mayfield CK et al. Am J Sports Med. 2026 (PMID: 41476424)
- Anti-doping / forensic detection in urine and plasma (analytical methodology) In vitro only
- In vitro metabolism of CJC-1295 and CJC-1295 with DAC characterised; 19 major metabolites identified. LC-MS/MS method developed with LODs generally ≤1 ng/mL in urine. PMID 34665524 Memdouh S et al. Drug Test Anal. 2021;13(11-12):1730-1744.
- Nano-LC-Q/Orbitrap MS method for CJC-1295 (and other GHRH analogs) in urine validated per WADA guidelines; LOD ≤0.5 ng/mL; LOI 0.5–0.75 ng/mL. PMID 41138283 Uçaktürk E, Nemutlu E. J Pharm Biomed Anal. 2026 (PMID: 41138283)
- Immuno-PCR assay in equine plasma detected CJC-1295-protein conjugate down to 0.8 pg/mL; screening threshold of 50 pg/mL established. Confirmed illicit use in thoroughbred racehorses. PMID 30489688 Timms M et al. Drug Test Anal. 2019;11(7):1014-1023.
- Performance and image enhancement (bodybuilding/recreational use — characterised via netnography and forum analysis) Human observational
- Netnographic analysis of 23 female-focused online forum discussion threads about CJC-1295. Users reported using it for weight loss, muscle enhancement, youthful skin, improved sleep, and injury healing. Concerns were expressed about gender-specific dosage estimation and long-term consequences. PMID 26771670 Van Hout MC, Hearne E. Subst Use Misuse. 2016;51(9):1135-1142.
Safety signals
- No serious adverse reactions were reported in the two randomised, placebo-controlled clinical trials at doses of 30 or 60 µg/kg sc; the compound was described as 'safe and relatively well tolerated, particularly at doses of 30 or 60 µg/kg'. PMID 16352683
- Potential class-level adverse effects of GH-axis secretagogues include prolactin and cortisol elevations, appetite changes, dysglycaemia, fluid retention, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions — noted for GH-axis peptides as a group including CJC-1295. PMID 42395176
- Emerging data on GH secretagogues and related peptides used in sport highlight potential risks of cardiovascular strain, insulin resistance, dyslipidaemia, and psychiatric instability, though these are described as a class concern and not specifically quantified for CJC-1295 alone. PMID 41880199
- Indications, dosing, frequency, duration, safety, and efficacy of CJC-1295 for clinical or orthopaedic use remain unknown; significant research is required before definitive recommendations can be made. PMID 41476424
- Non-approved peptides including CJC-1295 lack long-term safety data and systematic validation; significant knowledge gaps include optimal dosing regimens and combination therapy effects. PMID 42021992
- Illicitly manufactured preparations containing CJC-1295 have been identified by law enforcement, raising concerns about product quality, purity, and contamination in the unregulated supply chain. PMID 21204297
- Widespread product mislabelling and contamination have been noted for peptides in the unregulated 'gray market', including CJC-1295; uncertain product composition, dose, and stacking practices increase risk. PMID 42395176
Contraindications
- Use by competitive athletes is prohibited under WADA regulations; competitive athletes are contraindicated from using CJC-1295 outside of an approved therapeutic use exemption. PMID 41138283
- The reviewed literature does not enumerate specific medical contraindications (e.g., pregnancy, malignancy, specific disease states) for CJC-1295. Absence of approval and absence of long-term human safety data preclude clinical use outside of research settings. PMID 41966639
Protocol
1000 mcg subcutaneous injection, once weekly. Cycle: 8-12 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Subcutaneous injection | Single doses studied (ascending): range not fully specified in abstract; well-tolerated doses cited as 30 or 60 µg/kg; multiple doses of 30 or 60 µg/kg administered weekly or biweekly | 28 days (Study 1); 49 days (Study 2) | human | Research PMID 16352683 |
| Injection (route not further specified in abstract) | 60 or 90 µg/kg (single injection) | Single dose; GH/IGF-1 assessed over 12-hour overnight sampling period 1 week post-injection | human | Research PMID 17018654 |
| Injection (route not further specified in abstract) | Not explicitly stated (single injection; dose not specified in abstract) | Single dose; serum assessed 1 week post-injection | human | Research PMID 19386527 |
| Not specified in abstract | 2 µg per animal at intervals of 24, 48, or 72 hours | 5 weeks | animal | Research PMID 16822960 |
| Subcutaneous injection | Not explicitly stated (dose used in GH AUC comparison with hGRF(1-29) not numerically specified in abstract) | Single dose; plasma measured beyond 72 h | animal | Research PMID 15817669 |
| Not specified in abstract | Not explicitly stated in abstract | Not explicitly stated in abstract | animal | Research PMID 19332789 |
| subcutaneous injection | 1000 mcg | once weekly · 8-12 weeks | biohackers and bodybuilders seeking GH pulse amplification and anabolic/body composition effects | [Community] |
| subcutaneous injection | 2000 mcg | once weekly · 8-12 weeks | experienced biohackers and bodybuilders seeking aggressive GH optimization | [Community] |
| subcutaneous injection | 500 mcg | once weekly · 8-12 weeks | beginners or older adults titrating in cautiously; longevity-focused biohackers | [Community] |
| subcutaneous injection | 1000 mcg | once weekly · 12-24 weeks | longevity-focused adults and anti-aging clinic patients on TRT or hormone optimization protocols | [Community] |
| subcutaneous injection | 1000 mcg | twice weekly · 8-12 weeks | intermediate-to-advanced bodybuilders and biohackers wanting more frequent GH elevation with DAC | [Community] |
Blends containing this peptide
All studies (19)
- PMID 16352683 Human RCT
Stimulation of GH and IGF-1 secretion in healthy adults (pharmacokinetic/pharmacodynamic characteris - PMID 17018654 Human RCT
Stimulation of GH and IGF-1 secretion in healthy adults (pharmacokinetic/pharmacodynamic characteris - PMID 19386527 Human observational
Identification of GH/IGF-1-related serum protein biomarkers - PMID 26771670 Human observational
Performance and image enhancement (bodybuilding/recreational use — characterised via netnography and - PMID 15817669 Animal studies only
Normalisation of growth in GHRH-deficient (knockout) mice - PMID 16822960 Animal studies only
Normalisation of growth in GHRH-deficient (knockout) mice - PMID 19332789 Animal studies only
Rescue of growth deficit in brain-specific M3 muscarinic receptor knockout mice - PMID 21204297
Illicitly manufactured preparations containing CJC-1295 have been identified by law enforcement, raising concerns about product quality, purity, and contaminati - PMID 26879649
- PMID 30489688 In vitro only
Anti-doping / forensic detection in urine and plasma (analytical methodology) - PMID 34665524 In vitro only
Anti-doping / forensic detection in urine and plasma (analytical methodology) - PMID 35298973
- PMID 41138283 In vitro only
Anti-doping / forensic detection in urine and plasma (analytical methodology) - PMID 41476424 Animal studies only
Improvement of muscle performance in glucocorticoid-induced muscle loss (murine model) - PMID 41490200
- PMID 41880199
Emerging data on GH secretagogues and related peptides used in sport highlight potential risks of cardiovascular strain, insulin resistance, dyslipidaemia, and - PMID 41966639
The reviewed literature does not enumerate specific medical contraindications (e.g., pregnancy, malignancy, specific disease states) for CJC-1295. Absence of ap - PMID 42021992
Non-approved peptides including CJC-1295 lack long-term safety data and systematic validation; significant knowledge gaps include optimal dosing regimens and co - PMID 42395176
Potential class-level adverse effects of GH-axis secretagogues include prolactin and cortisol elevations, appetite changes, dysglycaemia, fluid retention, muscu
Frequently asked
What is CJC-1295 and how does it work?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It contains a reactive group that covalently binds to serum albumin in the bloodstream, extending its half-life to approximately 5.8–8.1 days. This prolonged action stimulates the pituitary gland to release growth hormone (GH) in a sustained, dose-dependent manner, which in turn raises IGF-1 levels. GH pulsatility is preserved, but trough GH levels are markedly elevated.
Has CJC-1295 been tested in humans?
Yes, but only in limited clinical studies. Two randomised, placebo-controlled trials in healthy adults (ages 21–61 years) evaluated CJC-1295 pharmacokinetics, GH/IGF-1 responses, and safety over up to 49 days. A separate clinical study assessed GH pulsatility in healthy men after a single dose. A small proteomic study examined serum biomarker changes in 11 healthy men one week post-injection. No large-scale clinical trials evaluating long-term safety or efficacy for any specific medical indication are described in the reviewed literature.
What dose of CJC-1295 should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: In the published human clinical trials, doses of 30 or 60 µg/kg administered subcutaneously (single or weekly/biweekly doses) were described as well tolerated. Doses of 60 or 90 µg/kg were studied in a single-dose pulsatility study. These were investigational research settings, not clinical treatment protocols, and the authors of multiple reviews note that dosing, frequency, and duration for any clinical use remain unknown.
Is CJC-1295 legal to use?
CJC-1295 is prohibited by the World Anti-Doping Agency (WADA) as a growth hormone-releasing hormone analogue. It has not been approved by regulatory authorities (e.g., FDA) for performance enhancement or general clinical use. An illicitly manufactured pharmaceutical preparation containing CJC-1295 was identified by Norwegian police and customs authorities. Regulatory status in specific countries should be verified with a licensed healthcare provider or legal professional, as the reviewed literature does not address all jurisdictions.
Can CJC-1295 help with muscle growth or recovery?
Animal studies suggest potential benefits: CJC-1295 combined with ipamorelin improved maximum tetanic tension in mice with glucocorticoid-induced muscle loss, and CJC-1295 alone normalised growth and body composition in growth hormone-deficient mice. However, multiple reviews conclude that human evidence for musculoskeletal recovery or muscle enhancement is lacking, that these findings have not been validated in clinical trials, and that definitive recommendations cannot currently be made.
What are the side effects or safety concerns with CJC-1295?
In the two randomised human trials, no serious adverse reactions were reported at doses of 30 or 60 µg/kg. However, long-term safety data are absent. Class-level concerns for GH-axis peptides include prolactin/cortisol elevations, appetite changes, dysglycaemia, fluid retention, myalgia/arthralgia, and injection-site reactions. Broader concerns for peptides in this category include cardiovascular strain, insulin resistance, dyslipidaemia, and psychiatric instability. Products from unregulated sources may be mislabelled or contaminated. Significant research gaps remain regarding long-term safety.
Can I stack CJC-1295 with ipamorelin or other peptides?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: CJC-1295 combined with ipamorelin showed improved maximum tetanic tension in a murine glucocorticoid-induced muscle loss model. However, safety and efficacy data for stacked protocols in humans are not available in the reviewed literature. Reviews note that combination therapy effects and stacking practices in unregulated settings carry uncertain and potentially increased risks.
Where can I buy CJC-1295?
I don't recommend vendors or sources. Please consult a licensed provider.
Will CJC-1295 show up on a drug test?
Yes. Multiple validated analytical methods have been developed specifically to detect CJC-1295 in urine and plasma for anti-doping purposes. Limits of detection as low as 0.2 ng/mL in urine and 0.8 pg/mL in equine plasma have been reported. CJC-1295 is on the WADA Prohibited List, and detection methods have been applied to competitive sports doping control samples.
Can CJC-1295 help with anti-aging or longevity?
CJC-1295 has been discussed in the context of growth hormone modulation as a potential approach to aging-related hormonal decline. However, the same review notes that non-approved peptides including CJC-1295 lack long-term safety data and systematic validation, and that significant knowledge gaps exist regarding optimal dosing, combination effects, and biomarkers for monitoring efficacy. No clinical evidence supporting anti-aging or longevity benefits in humans is described in the reviewed literature. I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider.